1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
Jennifer A. Chan(Dana-Farber Cancer Institute), Susan M. Geyer(Mayo Clinic), Tyler Zemla(Mayo Clinic), Michael V. Knopp(University of Cincinnati), Spencer C. Behr(University of California, San Francisco), Sydney Pulsipher(Mayo Clinic), Jared D. Acoba(University of Hawaiʻi at Mānoa), Ardaman Shergill(University of Chicago), Edward M. Wolin(Icahn School of Medicine at Mount Sinai), Þorvarður R. Hálfdánarson(Mayo Clinic in Arizona), Bhavana Konda(The Ohio State University), Nikolaos A. Trikalinos(Washington University in St. Louis), Shagufta Shaheen(Stanford Medicine), N. Vijayvergia(Fox Chase Cancer Center), N.A. Dasari(The University of Texas MD Anderson Cancer Center), J. Strosberg(Moffitt Cancer Center), Elise C. Kohn(National Cancer Institute), Matthew Kulke(Boston Medical Center), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Jeffrey A. Meyerhardt(Dana-Farber Cancer Institute)
Cited by 1
Abstract
Related Papers
No related papers found
Powered by citation graph analysis